Pramipexole and Levodopa in Early Parkinson??s Disease
- 1 January 2005
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 23 (12) , 1257-1270
- https://doi.org/10.2165/00019053-200523120-00009
Abstract
Background and Objective:In chronic disease, treatment effects and costs accumulate over time; hence, the choice of time horizon in cost-effectiveness analysis can be particularly important. In this...Keywords
This publication has 42 references indexed in Scilit:
- FDA Attempting To Overcome Major Roadblocks in Monitoring Drug SafetyJNCI Journal of the National Cancer Institute, 2005
- US Valuation of the EQ-5D Health StatesMedical Care, 2005
- Taking account of future technology in cost effectiveness analysisBMJ, 2004
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002
- Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson??s DiseasePharmacoEconomics, 2001
- Health related quality of life in Parkinson's disease: a prospective longitudinal studyJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Cost of Illness and Disease Severity in a Cohort of French Patients with Parkinson??s DiseasePharmacoEconomics, 1999
- Cost Effectiveness of Pramipexole in Parkinson??s Disease in the USPharmacoEconomics, 1998
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994